The 7 most recent market catalysts affecting $BRVE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 95
Braveheart Bio Q2 EPS $(2.51)
Braveheart Bio (BRVE) announced Q2 earnings per share of $(2.51), which not only missed analyst consensus estimates of $0.74 by a staggering 439.19% but also represented a 1692.86%…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 75
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Goldman Sachs, a prominent investment bank, has initiated coverage on Braveheart Bio (BRVE) with a 'Buy' rating and a $48 price target. This event is significant as it signals a ma…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
TD Cowen Initiates Coverage On Braveheart Bio with Buy Rating
TD Cowen analyst Tyler Van Buren has initiated coverage on Braveheart Bio (BRVE) with a 'Buy' rating. This event is significant because analyst initiations, especially with a posit…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 75
Jefferies Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Jefferies initiating coverage on Braveheart Bio with a 'Buy' rating and a $48 price target is a significant positive catalyst for the company. Analyst coverage, especially from a p…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40
Cantor Fitzgerald's initiation of coverage on Braveheart Bio with an 'Overweight' rating and a $40 price target is a positive development for the company. Analyst coverage, especia…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 75
Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45
Stifel analyst James Condulis has initiated coverage on Braveheart Bio (BRVE) with a 'Buy' rating and a $45 price target. This event is significant because new analyst coverage, es…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 55
BRVE Amends Charter, Bylaws for IPO Completion; Authorizes 500M Common Shares
This 8-K filing from Braveheart Bio, Inc. (BRVE) details the formal amendments to its corporate governance documents, specifically its Certificate of Incorporation and Bylaws, whic…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.